Logo

SomaLogic Raises $16.5M

Nov 03, 2014 | staff reporter

NEW YORK (GenomeWeb) – In a notice filed on Friday with the US Securities and Exchange Commission, SomaLogic disclosed that it has raised $16.5 million.

According to the SEC document, the sale took place on Oct. 17 with equity going to two unidentified investors.

Last month, Novartis agreed to take an equity stake in SomaLogic as part of an extension of a multi-year agreement between the two companies. It is unclear if the recent financing relates to that agreement. SomaLogic declined to comment on the offering or identify the investors.

Filed under

Proteomics & Protein Research
proteomics
Somalogic
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.